期刊文献+

泮托拉唑联合莫沙必利与单用莫沙必利治疗功能性消化不良的疗效比较 被引量:4

下载PDF
导出
摘要 目的探讨泮托拉唑联合莫沙必利与单用莫沙必利治疗功能性消化不良(FD)的疗效比较。方法选择80例FD患者,随机分为观察组和对照组。两组患者均予以莫沙必利胶囊5mg,每天3次,餐前30min服用,连用4周。观察组在此基础上加用泮托拉唑钠肠溶胶囊20mg,每天1次,连用4周。观察并比较两组患者治疗后的临床疗效和不良反应。结果治疗4周后,观察组的临床总有效率明显高于对照组(χ2=6.05,P<0.05)。观察组与对照组治疗期间分别发生不良反应2例和4例,症状均较轻,无严重的不良反应。两组治疗期间不良反应发生率比较无明显统计学差异(χ2=0.18,P>0.05)。结论泮托拉唑联合莫沙必利治疗FD的临床疗效确切,可迅速、持续缓解患者的临床症状,安全性较好,是一种治疗FD安全有效的方法。
出处 《海峡药学》 2012年第11期220-221,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献10

二级参考文献40

  • 1刘瑞,黄明慧,李献,强欧,唐承薇,邓岸黎.枸橼酸莫沙必利分散片对豚鼠胃排空的影响[J].胃肠病学,2005,10(2):103-106. 被引量:33
  • 2王宝恩,梁晓梅,贾博琦,陈宝雯,柯美云,林三仁,丁士刚,张锦坤,施礼,张志宏,陈隆典,徐家裕,袁耀宗,阮美娟,刘厚钰,邱德凯,张达荣,李增烈,欧阳钦,王一平,李瑜元,吴惠生,胡家露,姜若兰,王莜如,梁有信.西沙必利治疗功能性消化不良的多中心临床疗效观察[J].中华内科杂志,1995,34(3):180-184. 被引量:112
  • 3柯美云.功能性胃肠病并非单纯功能病[J].中国实用内科杂志:临床前沿版,2006,26(5):721-722. 被引量:65
  • 4杨纯英,周夏丰,林刚.PPI治疗非溃疡性消化不良360例疗效观察[J].浙江预防医学,2006,18(11):76-77. 被引量:3
  • 5吴宗英,王一平,曾超.莫沙必利治疗功能性消化不良的系统评价[J].中国循证医学杂志,2006,6(11):790-803. 被引量:47
  • 6周吕 柯美云 潘国宗 曹世植 主编.胃运动生理与病理生理及检查方法[A].潘国宗,曹世植,主编.现代胃肠病学:第1版[C].北京:科学出版社,1994.842-861.
  • 7Padol S, Yuan Y, Thabane M, et al. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors : a review of a special problem [J]. Int J Clin Pharmacol Ther,2007,45(3) : 188.
  • 8Peura D A, Kovacs T O, Metz D C, et al. Lansoprazole in the treatment of functional dyspepsia : two double-blind, randomized, placebo-controlled trials [J]. Am J Med, 2004, 116( 11 ) : 781-782.
  • 9van Zanten S V, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial [J]. Am J Gastroenterol,2006, 101 (9) : 2096-2106.
  • 10[1]Drossman DA,Corazziari E,Talley NJ,et al.The functional gastrointestinal disorders(2nd edition):virgina Degnon Associates,2000

共引文献437

同被引文献41

  • 1王润梅.联合应用莫沙必利和黛力新治疗功能性消化不良42例的疗效分析[J].当代医药论丛,2014,12(1):57-58. 被引量:12
  • 2Sodhi JS, Javid G, Zargar SA, Tufail S, Shah A, Khan BA, Yattoo GN, Gulzar GM, Khan MA, Lone MI, Saif Ru, Parveen S, Shoukat A. Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. J Gastroenterol Hepatol 2013; 28: 808-813 [PMID" 23432600 DOI" 10.1111/jgh.12178].
  • 3Tack J, Talley NJ. Functional dyspepsia-symptoms, definitions and validity of the Rome Ⅲ criteria. Nat Rev Gastroenterol Hepatol 2013; 10:134-141 [PMID: 23399526 DOI: 10.1038/nrastro.2013.14].
  • 4张庆芝.综合性治疗功能性消化不良的临床研究.中外健康文摘,2013;50:18-19.
  • 5Quigley EM, Lacy BE. Overlap of functional dyspepsia and GERD-diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol 2013; 10:175-186 [PMID: 23296247 DOI: 10.1038/nrgas- tro.2012.253].
  • 6Camilleri vI, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 187-194 [PMID: 23381190 DOI: 10.1038/nrgas- tro.2013.11].
  • 7v j Talley NJ, Locke GR, Herrick LM, Silvernail VM, Prather CM, Lacy BE, DiBaise JK, Howden CW, Brenner DM, Bouras EP, E1-Serag HB, Abraham BP, Moayyedi P, Zinsmeister AR. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, random- ized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psy- chopathology, pathophysiology and pharmacoge- netics. Contemp Clin Trials 2012; 33:523-533 [PMID: 22343090 DOI: 10.1016/j.cct.2012.02.002].
  • 8郭文娟.功能性消化不良症状与机制的研究.北京:北京协和医学院中国医学科学院,2013.
  • 9Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adap- tive changes and target organ damage. ] Hypertens 2005; 23:247-250 [PMID: 15662208].
  • 10Tabit CE, Chung WB, Hamburg NM, Vita JA. Endo- thelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11:61-74 [PMID: 20186491 DOI: 10.1007 / s11154-010-9134-4].

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部